Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Carla, Johnson & Johnson, Mevion, Opus, Pfizer, Polaroid, Scopbio, Siren, Vanda, Viatris, Xenocor.
Biopharma and med-tech companies raising money in public or private financings, including: Abram, Bicara, Breezebio, Octapharma, Respiree, Trinity, Zura.
New hires and promotions in the biopharma and med-tech industries, including: Alkermes, Ascensia, Caredx, Cosmos Health, Geovax, Karoo, Rivus, Seebelife, Transpire.
U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.
Eli Lilly and Co. got a breather when the U.S. Ninth Circuit Court of Appeals agreed that the company doesn’t owe Research Corporation Technologies Inc. (RCT) royalties on its diabetes drugs under a licensing agreement Lilly had made with Phillips Petroleum Co. in 1990 and that Phillips later sold to RCT.
China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.
The U.S. FDA approved Allurion Technologies Inc.’s premarket application for its swallowable gastric balloon system, which features its Smart Capsule, for weight loss. The clearance is boon for the company as GLP-1 agonists gets increasingly adopted to treat obesity. The approval also brings to the market a new non-invasive option to patients looking for alternative ways to lose weight.
The BioWorld Biopharmaceutical Index finished 2025 up 24.07%, building slightly on its 23% gain recorded at the end of November. While the increase trailed the Nasdaq Biotechnology Index’s 32.4% rise for the year, it outperformed the broader Dow Jones Industrial Average, which advanced 12.97%.
RSS
